Hormonal receptor positive breast cancer adjuvant and metastatic indications
Dr Simona Rossi talks about ObTiMA as a clinical trial management tool, her involvement in the usability of the tool and the difference it will make to doctors and patients.
Read our Special Issue on the Personalized Medicine project.
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Synthetic biology and precision medicine in blood and gynaecological cancers
Early-stage breast cancer detection in breast milk
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Moving to the future: Artificial intelligence in surgery